What the label lists and what reports show
Teriparatide side effects
Teriparatide's FDA label: “Most common adverse reactions (>10%) include: arthralgia, pain, and nausea” FAERS holds 112,087 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is nausea (9,007 reports).
- Generic listed
Check it at the source: the teriparatide FDA label on DailyMed (effective August 3, 2026, Eli Lilly and Company); the FDA FAERS public dashboard.
What does the patient leaflet say about side effects?
From the patient leaflet: What are the possible side effects of FORTEO?FORTEO may cause serious side effects including: See “ What is the most important information I should know about FORTEO? ” Bone cancer (osteosarcoma): Tell your healthcare provider right away if you have pain in your bones, pain in any areas of your body that does not go away, or any new or unusual lumps or swelling under your skin that is tender to touch. Increased calcium in your blood: Tell your healthcare provider if you have nausea, vomiting, constipation, low energy, or muscle weakness. These may be signs there is too much calcium in your blood. Worsening of your kidney stones: If you have or have had kidney stones your healthcare provider may check the calcium levels in your urine while you use FORTEO to see if there is worsening of this condition. […]
Source: FDA drug label, Eli Lilly and Company, effective August 3, 2026 (SPL set aae667c5-381f-4f92-93df-2ed6158d07b0), via openFDA; the full label on DailyMed
What does the label list?
From the label: adverse reactionsMost common adverse reactions (>10%) include: arthralgia, pain, and nausea
Table 1: Percentage of Patients with Adverse Events Reported by at Least 2% of FORTEO-Treated Patients and in More FORTEO-Treated Patients than Placebo-Treated Patients from the Two Principal Osteoporosis Trials in…
| Event Classification | FORTEO N=691 (%) | Placebo N=691 (%) |
|---|---|---|
| Pain | 21.3 | 20.5 |
| Headache | 7.5 | 7.4 |
| Asthenia | 8.7 | 6.8 |
| Neck pain | 3.0 | 2.7 |
| Hypertension | 7.1 | 6.8 |
| Angina pectoris | 2.5 | 1.6 |
| Syncope | 2.6 | 1.4 |
| Nausea | 8.5 | 6.7 |
| Constipation | 5.4 | 4.5 |
| Diarrhea | 5.1 | 4.6 |
| Dyspepsia | 5.2 | 4.1 |
| Vomiting | 3.0 | 2.3 |
| Gastrointestinal disorder | 2.3 | 2.0 |
| Tooth disorder | 2.0 | 1.3 |
| Arthralgia | 10.1 | 8.4 |
| Leg cramps | 2.6 | 1.3 |
| Dizziness | 8.0 | 5.4 |
| Depression | 4.1 | 2.7 |
| Insomnia | 4.3 | 3.6 |
| Vertigo | 3.8 | 2.7 |
| Rhinitis | 9.6 | 8.8 |
| Cough increased | 6.4 | 5.5 |
| Pharyngitis | 5.5 | 4.8 |
| Dyspnea | 3.6 | 2.6 |
| Pneumonia | 3.9 | 3.3 |
Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.
From the label: adverse reactions, continuedThe following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [ see Warnings and Precautions ( 5.1 ) ] Osteosarcoma [ see Warnings and Precautions ( 5.2 ) ] Hypercalcemia and Cutaneous Calcification [ see Warnings and Precautions ( 5.3 ) ] Risk of Urolithiasis [ see Warnings and Precautions ( 5.4 ) ] Orthostatic Hypotension [ see Warnings and Precautions ( 5.5 ) ] Risk of Digoxin Toxicity [ see Warnings and Precautions ( 5.6 ) ] Most common adverse reactions (>10%) include: arthralgia, pain, and nausea ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Men with Primary or Hypogonadal Osteoporosis and Postmenopausal Women with Osteoporosis The safety of FORTEO in the treatment of osteoporosis in men and postmenopausal women was assessed in two randomized, double-blind, placebo-controlled trials of 1382 patients (21% men, 79% women) aged 28 to 86 years (mean 67 years) [see Clinical Studies ( 14.1 , 14.2 )]. …
Source: FDA drug label, Eli Lilly and Company, effective August 3, 2026 (SPL set aae667c5-381f-4f92-93df-2ed6158d07b0), via openFDA; the full label on DailyMed
What do FAERS reports show?
112,087 reports list teriparatide among the medicines taken, each a report of something that happened, not proof the medicine caused it; 5,304 are coded as a death and 24,200 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 23 reactions below, 10 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.
Reports received each year
The 25 most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms
What next?
- Teriparatide: the full record
- label, generics, price, shortages, recalls
- Report a side effect to the FDA
- MedWatch
- Side effects hub
- the most reported medicines and reactions